Skip to main content

Clinical Trials Using Carboplatin

Review the clinical trials studying carboplatin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 251-266 of 266

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
Status: Active
Location: See ClinicalTrials.gov
A Cancer Vaccine (STEMVAC) in Combination with Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Acetylcysteine for the Mitigation of Chemotherapy-Related Cognitive Impairment in Ovarian Cancer Patients Receiving Platinum-Based Therapy
Status: Approved
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: 3 locations
Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Status: Temporarily Closed to Accrual
Location: 418 locations
Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Status: Temporarily Closed to Accrual
Location: 174 locations
Olaparib, Cabazitaxel, Carboplatin, and Prednisone in Treating Patients with Metastatic Prostate Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin for the Treatment of Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina
Vactosertib for the Treatment of Patients who are Undergoing Standard of Care Chemoradiation for Locally Advanced Esophageal Cancer
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Stereotactic Body Radiotherapy in Combination with Durvalumab, Cisplatin or Carboplatin, and Etoposide for Treatment of Refractory Extensive Stage Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Status: Active
Location: 1112 locations
Cell-Free Tumor DNA Testing for Deciding When to Start Routine Treatment in Patients with Human Papillomavirus-Associated Oropharynx Cancer
Status: Active
Location: 8 locations
Implantable Microdevice for the Evaluation of Drug Response in Patients with Prostate Cancer
Status: Active
Location: 2 locations
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Status: Active
Location: VA Puget Sound Health Care System, Seattle, Washington
Evaluation of De-Escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California